Navigation Links
Aptilon Announces Acquisition of Direct Medical Data, LLC and BLM Incorporated and Concurrent Private Placements
Date:9/18/2009

's service offering is based on its enterprise-class, SQL relational database which enables DMD to create data-driven extracts that power client initiatives.

The purchase of the Purchased Assets has been made through DMD Marketing LP, a Delaware limited partnership (the "New LP"), and its wholly-owned subsidiary DMD Marketing Corp., a Delaware corporation ("Newco"), which are both indirect affiliates of Aptilon. The Purchased Assets include office equipment, accounts receivables, rights under various contracts, licenses and leases, intellectual property, books, records, files and other data and assets.

The total consideration for the Purchased Assets is estimated at US $31,677,072, subject to adjustment based on the net working capital as of the Closing Date, comprised of US $2,000,000 in cash, US $27,200,000 by way of non-convertible, non-interest bearing promissory note repayable on a monthly basis over a period of three years with a lump sum payment of approximately US $12,417,000 on the third anniversary of the Closing (or four years with a lump sum payment of approximately US $7,417,000 on the fourth anniversary of the Closing if New LP and Newco exercise an extension right), and approximately US $1,643,738 by the issuance of 15,000,000 common shares of Aptilon at approximately CDN $0.11163 per share. In addition, the purchasers assume various liabilities and obligations of the sellers including the assumption of a debt in the amount of approximately US $833,333 and the accounts payable of DMD.

The common shares of Aptilon issued pursuant to this acquisition are subject to a four-month hold period, in accordance with applicable securities legislation and policies of the TSX Venture Exchange. The parties have agreed that certificates representing 7,500,000 of the 15,000,000 common shares of Aptilon will be put in escrow with an escrow agent for a period of one year. The escrow agreement provides for an early release of the shares in vario
'/>"/>

SOURCE APTILON CORPORATION
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Survey Indicates "Highest-Value" Physicians Most Likely to Participate in Aptilons Live Video Detailing Service
2. International Isotopes Inc. Announces Successful Completion of a Private Placement
3. HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for $142 Million
4. avVaa World Health Care Products, Inc. Announces Updated Financials
5. China Medical Technologies Announces US$30 Million Share Repurchase Program
6. Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics
7. 4 Stair Lifts Announces Grand Opening of Online Store
8. SXC Health Solutions announces pricing of upsized public offering of common shares
9. VIVUS Announces Pricing of Public Offering of Common Stock
10. Medical Malpractice Victim Helps Uphold Constitutional Rights of Patients in Washington State Supreme Court Decision, Perey Law Announces
11. Hill-Rom Announces CEO Succession Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 20, 2014 Women’s health specialist, Dr. ... & Gynecology of Columbus, Inc., A Division of MaternOhio ... to more than 100,000 patients annually. Dr. Murphy will ... and stages of a women’s life. She is accepting ... in Westerville and Dublin. , Dr. Murphy offers a ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... people suffering from tension-headaches, acupuncture may be the right ... BMJ said that acupuncture can reduce the incidence of ... the gold standard of clinical trials - researchers in ... tension headache into three groups. ,Over an ...
... Streptococcus suis and the first case was reported in June// ... mostly farmers and butchers, who handled infected pigs or people ... China, the infected pigs are thought to have come from ... 70 areas in and around the two cities of Ziyang ...
... new study says//. ,Phillip Marucha, and his colleagues ... study of laboratory mice, found that psychological stress, brought ... more than 45 percent, reports science portal eurekalert.org. ... for the slow recovery, it said. ,"The ...
... of Michigan Cardiovascular Center had presented new findings// ... that can cure inflammations in patients who had ... ,In a recent study the scientists had found ... several weeks after transplant surgery prevented the development ...
... be unconscious and happen even when people are not aware ... July 28, 2005 issue of Nature. ,Researchers from University ... Diego Veterans Affairs Health System had undertaken the study to ... formed even when they are actually not aware of doing ...
... neurodegenerative and ultimately fatal disease// that slowly destroys the ... the ability to take care of themselves and require ... ,Based on findings of a recent study researchers say ... help slow the progression of Alzheimer's disease by reducing ...
Cached Medicine News:Health News:Acupuncture May Be An Effective Treatment Against Tension-Headaches 2Health News:Research Shows Carbon Monoxide Prevents Inflammations 2Health News:Habit Memory May Enhance Learning In People 2
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... A of Trial Assessing Regimen of ... TUSTIN, Calif., Oct. 7 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... for the treatment of cancer and,hepatitis C virus (HCV) ... first stage of a Phase II trial of bavituximab ...
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
Cached Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
... Peel PRESTIGE system was designed with advanced ... of the most demanding skin care practice. ... the Parisian Peel PRESTIGE machine is designed ... to offer maximum versatility and full abrasion ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
Latex agglutination inhibition slide test for the qualitative detection of hCG in urine....
Test for the quantitative determination of antideoxyribonuclease-B (ADNase-B) in serum....
Medicine Products: